vs
德康医疗（DXCM）与凯旋（TFIN）财务数据对比。点击上方公司名可切换其他公司
凯旋的季度营收约是德康医疗的1.9倍（$2.4B vs $1.3B），德康医疗净利率更高（21.2% vs 0.3%，领先21.0%），德康医疗同比增速更快（21.6% vs 2.6%），过去两年凯旋的营收复合增速更高（377.6% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
凯旋汽车公司是19至20世纪活跃于英国的汽车与发动机制造企业，品牌起源可追溯到1885年。来自纽伦堡的齐格弗里德·贝特曼在伦敦成立公司，最初从欧洲进口自行车以自有商标销售，次年商标正式定为“凯旋”，1889年开始自主生产自行车。
DXCM vs TFIN — 直观对比
营收规模更大
TFIN
是对方的1.9倍
$1.3B
营收增速更快
DXCM
高出19.0%
2.6%
净利率更高
DXCM
高出21.0%
0.3%
两年增速更快
TFIN
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $2.4B |
| 净利润 | $267.3M | $6.4M |
| 毛利率 | 62.9% | 86.1% |
| 营业利润率 | 25.6% | — |
| 净利率 | 21.2% | 0.3% |
| 营收同比 | 21.6% | 2.6% |
| 净利润同比 | 153.6% | -66.9% |
| 每股收益（稀释后） | $0.67 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMTFIN
| Q1 26 | $1.3B | $2.4B | ||
| Q4 25 | $1.3B | $120.1M | ||
| Q3 25 | $1.2B | $109.3M | ||
| Q2 25 | $1.2B | $108.1M | ||
| Q1 25 | $1.0B | $101.6M | ||
| Q4 24 | $1.1B | $103.6M | ||
| Q3 24 | $994.2M | $106.2M | ||
| Q2 24 | $1.0B | $105.1M |
净利润DXCMTFIN
| Q1 26 | $267.3M | $6.4M | ||
| Q4 25 | $267.3M | — | ||
| Q3 25 | $283.8M | $1.7M | ||
| Q2 25 | $179.8M | $4.4M | ||
| Q1 25 | $105.4M | $17.0K | ||
| Q4 24 | $151.7M | $3.8M | ||
| Q3 24 | $134.6M | $5.3M | ||
| Q2 24 | $143.5M | $2.7M |
毛利率DXCMTFIN
| Q1 26 | 62.9% | 86.1% | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMTFIN
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | — | ||
| Q3 25 | 20.1% | 1.2% | ||
| Q2 25 | 18.4% | 7.3% | ||
| Q1 25 | 12.9% | 0.1% | ||
| Q4 24 | 17.0% | 5.6% | ||
| Q3 24 | 15.3% | 5.9% | ||
| Q2 24 | 15.7% | 3.4% |
净利率DXCMTFIN
| Q1 26 | 21.2% | 0.3% | ||
| Q4 25 | 21.2% | — | ||
| Q3 25 | 23.5% | 1.6% | ||
| Q2 25 | 15.5% | 4.1% | ||
| Q1 25 | 10.2% | 0.0% | ||
| Q4 24 | 13.6% | 3.7% | ||
| Q3 24 | 13.5% | 5.0% | ||
| Q2 24 | 14.3% | 2.6% |
每股收益（稀释后）DXCMTFIN
| Q1 26 | $0.67 | $0.23 | ||
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.70 | $0.04 | ||
| Q2 25 | $0.45 | $0.15 | ||
| Q1 25 | $0.27 | $-0.03 | ||
| Q4 24 | $0.37 | $0.13 | ||
| Q3 24 | $0.34 | $0.19 | ||
| Q2 24 | $0.35 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $950.7M |
| 总资产 | $6.3B | $6.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMTFIN
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $248.5M | ||
| Q3 25 | $1.8B | $147.2M | ||
| Q2 25 | $1.2B | $282.3M | ||
| Q1 25 | $904.9M | $502.9M | ||
| Q4 24 | $606.1M | $330.1M | ||
| Q3 24 | $621.2M | $489.3M | ||
| Q2 24 | $939.2M | $500.7M |
股东权益DXCMTFIN
| Q1 26 | $2.7B | $950.7M | ||
| Q4 25 | $2.7B | $941.8M | ||
| Q3 25 | $2.7B | $919.3M | ||
| Q2 25 | $2.6B | $912.4M | ||
| Q1 25 | $2.3B | $893.9M | ||
| Q4 24 | $2.1B | $890.9M | ||
| Q3 24 | $2.0B | $885.8M | ||
| Q2 24 | $2.4B | $874.2M |
总资产DXCMTFIN
| Q1 26 | $6.3B | $6.9B | ||
| Q4 25 | $6.3B | $6.4B | ||
| Q3 25 | $7.5B | $6.4B | ||
| Q2 25 | $7.3B | $6.5B | ||
| Q1 25 | $6.8B | $6.3B | ||
| Q4 24 | $6.5B | $5.9B | ||
| Q3 24 | $6.4B | $5.9B | ||
| Q2 24 | $6.8B | $5.8B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
